PURPOSE: Surgical infants requiring long-term parenteral nutrition (PN) are at risk for parenteral nutrition-associated liver disease (PNALD). The purpose of this study was to determine the effect of a lipid restricted PN regimen in preventing the development of PNALD in surgical infants. METHODS: In 2009, we implemented a lipid restricted strategy in surgical infants expected to be on long-term PN using a soy-based lipid emulsion at a goal provision of 1g/kg/day throughout a patient's entire PN course. An experimental cohort of surgical infants treated with lipid restriction from 2009 to 2011 (n=82) was retrospectively compared to a control cohort of infants from 2005 to 2008 receiving standard intravenous lipid dosing (n=132). A multivariable relative risk regression model was constructed analyzing the association between lipid restriction and PNALD. RESULTS: Patients admitted during the lipid restriction era had reduced daily lipid provisions compared to the control group (p<0.001). There were no significant differences in demographic or measured clinical characteristics between the two groups. A significant reduction in the incidence of PNALD was demonstrated in the lipid restricted group compared to the control group (22% vs. 43%, p=0.002). On multivariable relative risk regression, patients treated with standard lipid provisions were 1.77 times more likely to develop PNALD than patients who were lipid restricted (95% CI: 1.2-2.7; p=0.007). CONCLUSION: Restriction of intravenous soy-based lipid in PN-fed surgical infants is associated with a reduction in the incidence of liver disease. Early lipid restriction should be considered in all surgical infants who require PN as a preventative measure against PNALD.
PURPOSE: Surgical infants requiring long-term parenteral nutrition (PN) are at risk for parenteral nutrition-associated liver disease (PNALD). The purpose of this study was to determine the effect of a lipid restricted PN regimen in preventing the development of PNALD in surgical infants. METHODS: In 2009, we implemented a lipid restricted strategy in surgical infants expected to be on long-term PN using a soy-based lipid emulsion at a goal provision of 1g/kg/day throughout a patient's entire PN course. An experimental cohort of surgical infants treated with lipid restriction from 2009 to 2011 (n=82) was retrospectively compared to a control cohort of infants from 2005 to 2008 receiving standard intravenous lipid dosing (n=132). A multivariable relative risk regression model was constructed analyzing the association between lipid restriction and PNALD. RESULTS:Patients admitted during the lipid restriction era had reduced daily lipid provisions compared to the control group (p<0.001). There were no significant differences in demographic or measured clinical characteristics between the two groups. A significant reduction in the incidence of PNALD was demonstrated in the lipid restricted group compared to the control group (22% vs. 43%, p=0.002). On multivariable relative risk regression, patients treated with standard lipid provisions were 1.77 times more likely to develop PNALD than patients who were lipid restricted (95% CI: 1.2-2.7; p=0.007). CONCLUSION: Restriction of intravenous soy-based lipid in PN-fed surgical infants is associated with a reduction in the incidence of liver disease. Early lipid restriction should be considered in all surgical infants who require PN as a preventative measure against PNALD.
Authors: Patrick J Javid; Frances R Malone; André A S Dick; Evelyn Hsu; Maria Sunseri; Patrick Healey; Simon P Horslen Journal: J Pediatr Surg Date: 2011-10 Impact factor: 2.545
Authors: Mark Puder; Clarissa Valim; Jonathan A Meisel; Hau D Le; Vincent E de Meijer; Elizabeth M Robinson; Jing Zhou; Christopher Duggan; Kathleen M Gura Journal: Ann Surg Date: 2009-09 Impact factor: 12.969
Authors: Mary Petrea Cober; Ghassan Killu; Allison Brattain; Kathleen B Welch; Shaun M Kunisaki; Daniel H Teitelbaum Journal: J Pediatr Date: 2011-10-06 Impact factor: 4.406
Authors: Ivan R Diamond; Nicole T de Silva; George A Tomlinson; Paul B Pencharz; Brian M Feldman; Aideen M Moore; Simon C Ling; Paul W Wales Journal: JPEN J Parenter Enteral Nutr Date: 2011-08-08 Impact factor: 4.016
Authors: Roland N Dickerson; Vanessa J Kumpf; Carol J Rollins; Eric H Frankel; Michael D Kraft; Todd W Canada; Catherine M Crill Journal: Hosp Pharm Date: 2014-09
Authors: Bram P Raphael; Paul D Mitchell; Darryl Finkton; Hongyu Jiang; Tom Jaksic; Christopher Duggan Journal: J Pediatr Date: 2015-04-01 Impact factor: 4.406
Authors: Patrick J Javid; Assaf P Oron; Christopher P Duggan; Robert H Squires; Simon P Horslen Journal: J Pediatr Surg Date: 2017-09-05 Impact factor: 2.545
Authors: Gregory Guthrie; Madhulika Kulkarni; Hester Vlaardingerbroek; Barbara Stoll; Kenneth Ng; Camilia Martin; John Belmont; Darryl Hadsell; William Heird; Christopher B Newgard; Oluyinka Olutoye; Johannes van Goudoever; Charlotte Lauridsen; Xingxuan He; Edward H Schuchman; Douglas Burrin Journal: J Lipid Res Date: 2016-07-29 Impact factor: 5.922
Authors: Patrick M Chesley; Sabrina E Sanchez; Lilah Melzer; Assaf P Oron; Simon P Horslen; F Curt Bennett; Patrick J Javid Journal: J Pediatr Gastroenterol Nutr Date: 2016-07 Impact factor: 2.839
Authors: Orly L Levit; Kara L Calkins; L Caroline Gibson; Lorraine Kelley-Quon; Daniel T Robinson; David A Elashoff; Tristan R Grogan; Ning Li; Matthew J Bizzarro; Richard A Ehrenkranz Journal: JPEN J Parenter Enteral Nutr Date: 2014-06-24 Impact factor: 4.016